The Regulation of Plasma Interleukin-6 Levels Is Modified by Hippocampal Sclerosis and Its Lateralization in Drug-Resistant Temporal Lobe Epilepsy
Table 1
Demographics and clinical characteristics of patients.
Characteristics
TLE+HS
TLE-HS
XLE
IGE
34
103
92
36
F/M
22/12
46/57
47/45
22/14
Age, years
45 (18-69)
40 (17-76)
36 (17-70)
28 (16-56)
Age at onset, years
13 (1-42)
16 (0-59)
11 (0-60)
14 (4-49)
ILAE aetiology
Structural
34 (100)
43 (41.7)
52 (56.5)
Genetic
36 (100)
Immune
4 (3.9)
1 (1.1)
—
Infectious
8 (7.8)
3 (3.3)
—
Unknown
48 (46.6)
36 (39.1)
—
Duration of epilepsy, years
30.0 (4-57)
23.0 (2-70)
18.0 (0.4-55)
17.0 (1.4-40)
Seizure-free patients for 1 year before labs
2 (5.9)
16 (15.7)
13 (14.1)
14 (40.0)
At least one seizure 1 month before labs
26 (76.5)
68 (66.0)
60 (65.2)
14 (40.0)
Seizure frequency 1 month before labs
3.0 (0-10)
1.0 (0-60)
2 (0-95)
0.0 (0-5)
Autoimmune disease
4 (11.8)
10 (9.7)
6 (6.5)
2 (5.6)
Surgery
No surgery
26 (76.5)
83 (81.4)
79 (85.9)
36
Epilepsy surgery
7 (20.6)
10 (9.8)
2 (2.2)
0
Other lesional surgery
1 (2.9)
9 (8.8)
11 (12.0)
0
Presented as the median (range) for age, age at onset, seizure frequency 1 month before labs, and the duration of epilepsy or the frequency and proportion (for the rest of the variables). Abbreviations: TLE+HS: temporal lobe epilepsy with hippocampal sclerosis; TLE-HS: temporal lobe epilepsy without hippocampal sclerosis; XLE: extratemporal lobe epilepsy; IGE: idiopathic generalized epilepsy; ILAE: International League Against Epilepsy. One patient with TLE-HS had missing information on surgery.
